Connect with us

International News

Agilent and BioTek to Jointly Create a New Integrated Solution

Agilent Technologies Inc. and BioTek Instruments Inc. have joined forces to create a new, integrated solution that combines cellular metabolic analysis and imaging technologies. The optimized solution integrates the Agilent Seahorse XFe96/XFe24 Analyzers with the BioTek Cytation 1 Cell Imaging Multi-Mode Reader. This solution creates a standardized approach for comparing XF data sets, improving assay workflow, embedding images into WAVE software, and applying normalization values to Seahorse XF measurements.

Now researchers can toggle between XF data, brightfield images, and fluorescence images in a unified software experience. Referencing the images while analyzing XF data provides evidence and guidance on how to limit variability and improve the reproducibility of their XF assays. Applying a cell count based normalization value ultimately makes interpreting Seahorse XF data and finding relationships amongst the data easier. Agilent and BioTek will jointly market the integrated solution, planned for release in the United States of America and Europe in April 2018, and the rest of the world by June 2018.

“This integrated solution gives our customers the ability to compare XF data on a well-to-well, plate-to-plate, and experiment-to-experiment basis.”

David Ferrick
Senior Director – Cell Analysis Division,
Agilent

Click to comment

You must be logged in to post a comment Login

Leave a Reply

Copyright © 2024 Medical Buyer

error: Content is protected !!